Abstract.
Post-transplant lymphoproliferative disease (PTLD) is an uncommon but life-threatening complication of solid-organ and blood stem-cell transplants. It responds poorly to therapy, including reduction of immunosuppression, interferon, antivirals or chemotherapy. Small series of PTLD successfully treated with rituximab have been reported, and experimental studies suggest that rapamycin inhibits growth of human Epstein-Barr virus-transformed B lymphocytes. We report two cases of PTLD after renal transplantation that were successfully treated with rituximab in association with rapamycin. This report suggests that rituximab associated with rapamycin could be an effective and safe treatment for PTLD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
About this article
Cite this article
Garcia, V., Filho, J., Neumann, J. et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 16, 202–206 (2003). https://doi.org/10.1007/s00147-002-0487-9
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00147-002-0487-9